Fulranumab

also known as JNJ-42160443 · AMG 403

Monoclonal antibody targets NGF via inhibition

Developed for: osteoarthritis · osteoarthritis, knee · chronic pain syndrome · diabetic neuropathy · interstitial cystitis · mononeuropathy · neuropathy, painful · osteoarthritis, hip
+1 more
· postherpetic neuralgia
Investigated by: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · Janssen Research & Development, LLC · Amgen

Trials 13 · a red edge is where a trial was stopped

today NCT02336698 · Ph 3 NCT02289716 · Ph 3 NCT02336685 · Ph 3 NCT02301234 · Ph 3 NCT01094262 · Ph 2 NCT01060254 · Ph 2 NCT00993018 · Ph 2 NCT00929188 · Ph 2 NCT00973141 · Ph 2 NCT00964990 · Ph 2 NCT00973024 · Ph 2 NCT02318407 · Ph 1 NCT02348879 · Ph 1

20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 12 trials
Phase 1	NCT02318407	Dec 2006 → Jan 2008	osteoarthritis	Amgen	Completed	No outcome recorded
Phase 1	NCT02348879	Jan 2005 → Jan 2006	chronic pain syndrome	Amgen	Completed	No outcome recorded
Phase 27 trials
Phase 2	NCT01094262	Apr 2010 → Jul 2011	osteoarthritis, knee	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Terminated	No outcome recorded
Phase 2	NCT01060254	Apr 2010 → Jun 2011	interstitial cystitis	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Terminated	No outcome recorded
Phase 2	NCT00993018	Nov 2009 → Jun 2011	diabetic neuropathy	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Terminated	No outcome recorded
Phase 2	NCT00929188	Oct 2009 → Jan 2015	neuropathy, painful	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 2	NCT00973141	Sep 2009 → Jun 2011	osteoarthritis, hip, osteoarthritis, knee	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Terminated	No outcome recorded
Phase 2	NCT00964990	Sep 2009 → Jul 2011	mononeuropathy, postherpetic neuralgia	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Terminated	No outcome recorded
Phase 2	NCT00973024	Sep 2009 → May 2011	—	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Terminated	No outcome recorded
Phase 34 trials
Phase 3	NCT02336698	Jul 2015 → Sep 2016	osteoarthritis	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 3	NCT02289716	Jul 2015 → Oct 2016	osteoarthritis	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 3	NCT02336685	Jul 2015 → Sep 2016	osteoarthritis	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 3	NCT02301234	Mar 2015 → Sep 2016	osteoarthritis	Janssen Research & Development, LLC	Completed	No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 14 sources stand behind the page.

Field	Value	Cited text
Known as	fulranumab	“This study was designed to evaluate the efficacy and safety of fulranumab, a fully human monoclonal antibody directed against nerve growth factor (NGF), for pain relief in...” PMID 28056917 ↗ Jan 2017 5 “PURPOSE: Fulranumab is an investigational, fully human recombinant monoclonal antibody (IgG2) that neutralizes the biological actions of human nerve growth factor.” PMID 27101815 ↗ Apr 2016 NCT02336685 ↗ NCT02301234 ↗ NCT02289716 ↗ NCT02336698 ↗
Known as	AMG 403	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02318407 ↗ 1 NCT02348879 ↗
Known as	JNJ-42160443	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00973141 ↗ 4 NCT00993018 ↗ NCT00964990 ↗ NCT01094262 ↗ NCT00929188 ↗
Action	Inhibit	“neutralizes the biological actions of human nerve growth factor” PMID 27101815 ↗ Apr 2016 1 “Beta-nerve growth factor inhibitor” CHEMBL1743023 ↗
Modality	Monoclonal antibody	“Fulranumab is an investigational, fully human recombinant monoclonal antibody (IgG2)” PMID 27101815 ↗ Apr 2016
Route	Subcutaneous	“route=subcutaneous use” NCT00929188 ↗
Target	NGF	“Beta-nerve growth factor inhibitor” CHEMBL1743023 ↗